These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 29306112

  • 1. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
    Noble J, Gatault P, Sautenet B, Gaudy-Graffin C, Beby-Defaux A, Thierry A, Essig M, Halimi JM, Munteanu E, Alain S, Buchler M.
    J Clin Virol; 2018; 99-100():38-43. PubMed ID: 29306112
    [Abstract] [Full Text] [Related]

  • 2. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 4. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T, Borges K, Williams A, Banh T, Vasilevska-Ristovska J, Allen U, Parekh RS, Hébert D.
    Transplantation; 2018 Aug 16; 102(8):1391-1396. PubMed ID: 29377877
    [Abstract] [Full Text] [Related]

  • 5. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
    Liverman R, Serluco A, Nance G, George R, Rodriguez DS, Deshpande S, Mao C, Garro R, Yildirim I.
    Pediatr Transplant; 2023 Jun 16; 27(4):e14493. PubMed ID: 36945819
    [Abstract] [Full Text] [Related]

  • 6. The impact of viral load and time to onset of cytomegalovirus replication on long-term graft survival after kidney transplantation.
    Reischig T, Kacer M, Hruba P, Jindra P, Hes O, Lysak D, Bouda M, Viklicky O.
    Antivir Ther; 2017 Jun 16; 22(6):503-513. PubMed ID: 28091392
    [Abstract] [Full Text] [Related]

  • 7. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
    Schaenman J, Phonphok K, Spanuchart I, Duong T, Sievers TM, Lum E, Reed EF, Bunnapradist S.
    Transpl Infect Dis; 2021 Feb 16; 23(1):e13457. PubMed ID: 32892447
    [Abstract] [Full Text] [Related]

  • 8. Cytomegalovirus infection in a seroendemic renal transplant population: a longitudinal study of virological markers.
    Rao M, Finny GJ, Abraham P, Juneja R, Thomas PP, Jacob CK, Sridharan G.
    Nephron; 2000 Apr 16; 84(4):367-73. PubMed ID: 10754415
    [Abstract] [Full Text] [Related]

  • 9. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
    Reischig T, Vlas T, Kacer M, Pivovarcikova K, Lysak D, Nemcova J, Drenko P, Machova J, Bouda M, Sedivcova M, Kormunda S.
    J Am Soc Nephrol; 2023 May 01; 34(5):920-934. PubMed ID: 36749127
    [Abstract] [Full Text] [Related]

  • 10. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A, Potena L, Borgese L, Gibertoni D, Squarzoni D, Turello G, Petrisli E, Piccirilli G, Gabrielli L, Grigioni F, Lazzarotto T.
    J Clin Microbiol; 2018 Apr 01; 56(4):. PubMed ID: 29305542
    [Abstract] [Full Text] [Related]

  • 11. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
    Perrottet N, Manuel O, Lamoth F, Venetz JP, Sahli R, Decosterd LA, Buclin T, Pascual M, Meylan P.
    BMC Infect Dis; 2010 Jan 06; 10():2. PubMed ID: 20053269
    [Abstract] [Full Text] [Related]

  • 12. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I, Loginov R, Mäkisalo H, Höckerstedt K.
    J Clin Virol; 2015 Oct 06; 71():73-5. PubMed ID: 26318605
    [Abstract] [Full Text] [Related]

  • 13. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients.
    Khoury JA, Storch GA, Bohl DL, Schuessler RM, Torrence SM, Lockwood M, Gaudreault-Keener M, Koch MJ, Miller BW, Hardinger KL, Schnitzler MA, Brennan DC.
    Am J Transplant; 2006 Sep 06; 6(9):2134-43. PubMed ID: 16780548
    [Abstract] [Full Text] [Related]

  • 14. Impact of an ultrasensitive Cytomegalovirus quantitative nucleic acid test on Cytomegalovirus detection and therapy in renal transplant recipients.
    Beechar VB, Pouch SM, Phadke VK, Karadkhele G, Larsen CP, Woodworth MH.
    Transpl Infect Dis; 2024 Feb 06; 26(1):e14219. PubMed ID: 38158932
    [Abstract] [Full Text] [Related]

  • 15. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 16. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients.
    Helanterä I, Lautenschlager I, Koskinen P.
    Nephrol Dial Transplant; 2009 Jan 15; 24(1):316-20. PubMed ID: 18842670
    [Abstract] [Full Text] [Related]

  • 17. Genomic Markers Associated with Cytomegalovirus DNAemia in Kidney Transplant Recipients.
    Shapira G, Volkov H, Fabian I, Mohr DW, Bettinotti M, Shomron N, Avery RK, Arav-Boger R.
    Viruses; 2023 Nov 08; 15(11):. PubMed ID: 38005904
    [Abstract] [Full Text] [Related]

  • 18. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.
    Cameron BM, Kennedy SE, Rawlinson WD, Mackie FE.
    Pediatr Transplant; 2017 Feb 08; 21(1):. PubMed ID: 27704725
    [Abstract] [Full Text] [Related]

  • 19. Burden of cytomegalovirus DNAemia among pediatric renal transplant patients on antiviral prophylaxis: A hospital-based analysis.
    Mehta K, Al-Yabes O, Allen A, Williams A, Petrich A, Langlois V, Hébert D, Allen U.
    Pediatr Transplant; 2020 Feb 08; 24(1):e13650. PubMed ID: 31891234
    [Abstract] [Full Text] [Related]

  • 20. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.
    Transplantation; 2011 Jul 27; 92(2):217-23. PubMed ID: 21685829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.